-

Tempus Introduces Workspaces into its Lens Data Analytics Platform

Lens is trusted by nearly 100 institutions to uncover novel insights

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform. Workspaces is a private, coding-based cloud environment designed to unblock research and accelerate innovation. This new interface provides researchers a frictionless workflow for surfacing critical insights to power scientific discovery and development.

Lens is already trusted by nearly 100 institutions, including healthcare systems and biopharma companies, to power research that improves patient outcomes. Lens provides access to more than 200 petabytes of de-identified multimodal datasets, as well as a suite of tools that enable rapid time-to-insight, flexible analyses, and collaboration. In addition to Workspaces, other new features include the integration of Tempus One, an AI assistant that makes the vast amounts of data more accessible, and Cohort Builder, which helps define cohorts of interest by leveraging the platform’s rich molecular and clinical filters, including, cancer diagnosis, HLA genotype, comorbidities and more.

The new Workspaces feature enables users to easily leverage virtual machines designed to support a variety of research goals, query and analyze data directly in popular coding languages like python and R, and run tailored analyses using Tempus’s library of analytic templates. The flexibility it provides is the perfect complement to Lens’ other pre-built visualization tools that allow for faster time-to-insight and understand demographics, distribution, and prevalence across cohorts of interest.

“We’ve heavily invested in designing Lens to be the most seamless and fastest way to translate multimodal data into pivotal insights, and we’re proud that many institutions already rely on it for their research needs,” said Ryan Fukushima, Chief Operating Officer at Tempus. “Workspaces is flexible and fast, offering multiple virtual machine types to support diverse analytical needs and rapidly surface critical insights that can shape the future of oncology care."

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Tempus


Release Versions

Contacts

Social Media Profiles
More News From Tempus

Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a significant expansion of new indications to its AI-enabled Next platform ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Next establishes a new category of "real-time clinical intelligence" — a departure from legacy retrospective analyses and generic EHR alerts — designed to facilitate the delivery of precision m...

Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub, its AI-enabled smart physician platform. Tempus is making available its advanced, next-generation generative AI clinical co-pilot directly in Hub to power an agent-first experience for healthcare providers, allowing them to integrate the benefits of large language models and generative AI capabilities...

Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 29 - June 3, 2026 in Chicago, Illinois. “This year’s ASCO Annual Meeting marks a significant milestone for Tempus, as we are presenting our largest collection of accepted research to date,...
Back to Newsroom